Want to learn how clinical genomics dx are developed @MayoClinic? Hussam Al Kateb, Mayo Clinical Labs co-director of clinical genomics, shares how the world-renowned medical center develops LDTs, such as for gene fusions in solid tumors. insideprecisionmedicine.com/… via @Inside_PM

Alas, @TesseraTx's in vivo "Gene Writers." After years of copycat calls, does this work support the @FlagshipPioneer company as the developer of new genome engineering tech? insideprecisionmedicine.com/… @zhaoweiasu @GeneInvesting @yaireinhorn Thoughts? via @Inside_PM

@zhaoweiasu @GeneInvesting @yaireinhorn any takers?

You know the story of Goldilocks and 3x PCSK9i? @Merck's enlicitide is a macrocyclic peptide that occupies a “Goldilocks” space between small molecules and biologics. Could it lead to next-gen oral tx? Apple: tinyurl.com/BTBe48AP Spotify: tinyurl.com/BTBe48Sp insideprecisionmedicine.com/… @Inside_PM

Hoping the FBI doesn’t show up at my door in response to my @Inside_PM deep dive into the culling of FDA leadership, focusing on Makary’s resignation and the blocked publication of two COVID-19 vaccine safety studies accepted in medical journals. insideprecisionmedicine.com/… via @Inside_PM

In the 2000s, @MattRVerse saw tech skyrocketing—except clinical dx. Then 2 tragic genetic diagnoses in his family changed it all. So, he founded @NateraGenetics & @myomeinc to enable preemptive medical intervention. A rare mix: deep tech + deeply human. insideprecisionmedicine.com/…

Richard Dawkins is the Rick Rubin of science…”I have no technical ability. I know nothing about [science]. I know what I like and what I don't like. I'm decisive about what I like and what I don't like."

How you know you're about to arrive at the 2026 @AACR conference (that's obviously in #SanDiego given the @Rivian...or the top-down on my own little vehicle 🫠)

Pig organs haven’t delivered long-term. But @eGenesisBio is redefining success: not as a cure, but a bridge to eligibility for human organs. CEO Mike Curtis breaks down recent pig kidney transplant cases & how they’re prepping for larger clinical trials. shows.acast.com/67105af84872…

In April 2024, Ricky Chu got the call no parent is ready for: his almost-5-year-old son Skyler had Hunter syndrome (MPS II), a rare genetic disease with no cure. Within weeks, baby brother Ollie was diagnosed too—launching the Chu family into a whirlwind of insurance battles, international travel, and a race against time for treatment. Today, after nearly a dozen trips to the U.K. and infusions of a first-in-human gene therapy, both boys are mobile, verbal, bilingual—and living proof that relentless hope can rewrite the odds. There's a second side to the story, which goes back a decade before Ricky ever got the call. For over a decade, researcher Brian Bigger, clinicians Simon Jones and Rob Wynn (@MFTnhs), and Andrew McFadyen (The Isaac Foundation) have been in a battle to fund research, navigate clinical trials, and bring hope to children living with one of the rarest neurodegenerative diseases on the planet. This feature was incredibly impactful and eye-opening for me as to the almost insurmountable battle for rare disease families and patients to get life-saving care. insideprecisionmedicine.com/… via @Inside_PM

I also wanted to thank @podcastawards for being nominated as a 2025 finalist for their The Skeptics' Guide Science & Medicine Category!

With topics like organ replacement and mass preventative gene therapy, this convo with Boyang Wang of the VC Immortal Dragons has just the right amount of spice to kick off 2026. Apple: lnkd.in/gwBWDFhM Spotify: lnkd.in/gwd_dYbA shows.acast.com/67105af84872… via @acast